Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Docetaxel in Advanced Nonsquamous NSCLC
NCT03654027Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03654027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654027.